#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA4375425	A	Oral bioavailability in mouse at 5 mg/kg by LC-MS analysis	Mus musculus	2		organism-based format	Scientific Literature
2.	ALA4375430	A	AUC in mouse at 5 mg/kg, ip by LC-MS analysis	Mus musculus	2		organism-based format	Scientific Literature
3.	ALA4375432	A	AUC in mouse at 5 mg/kg, po by LC-MS analysis	Mus musculus	2		organism-based format	Scientific Literature
4.	ALA4375433	A	Tmax in mouse at 5 mg/kg, po by LC-MS analysis	Mus musculus	2		organism-based format	Scientific Literature
5.	ALA4375434	A	Tmax in mouse at 5 mg/kg, ip by LC-MS analysis	Mus musculus	2		organism-based format	Scientific Literature
6.	ALA4375435	A	Cmax in mouse at 5 mg/kg, po by LC-MS analysis	Mus musculus	2		organism-based format	Scientific Literature
7.	ALA4375436	A	Cmax in mouse at 5 mg/kg, ip by LC-MS analysis	Mus musculus	2		organism-based format	Scientific Literature
8.	ALA4375437	F	Anti-absorptive activity in loperamide-induced CD-1 mouse model of constipation assessed as improvement in stool weight at 5 mg/kg, po administered via gavage for 1 hr prior to loperamide challenge and measured after 3 hrs	Mus musculus	1		organism-based format	Scientific Literature
9.	ALA4375439	B	Inhibition of mouse slc26a3 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/iodide exchange preincubated for 10 mins followed by NaI-substituted PBS addition and measured by YFP-based fluorescence assay	Mus musculus	45		cell-based format	Scientific Literature
10.	ALA4375440	B	Inhibition of mouse slc26a3 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/bicarbonate exchange by measuring decrease in cytoplasmic alkalinization by BCECF probe-based fluorescence assay	Mus musculus	2		cell-based format	Scientific Literature
11.	ALA4375441	B	Inhibition of mouse slc26a4 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/iodide exchange at 10 uM preincubated for 10 mins followed by NaI-substituted PBS addition and measured by YFP-based fluorescence assay	Mus musculus	2		cell-based format	Scientific Literature
12.	ALA4375442	B	Inhibition of mouse slc26a6 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/iodide exchange at 10 uM preincubated for 10 mins followed by NaI-substituted PBS addition and measured by YFP-based fluorescence assay	Mus musculus	2		cell-based format	Scientific Literature
13.	ALA4375443	B	Inhibition of human slc26a9 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/iodide exchange at 10 uM preincubated for 10 mins followed by NaI-substituted PBS addition and measured by YFP-based fluorescence assay	Homo sapiens	2		cell-based format	Scientific Literature
14.	ALA4375445	A	Drug uptake in mouse serum at 5 mg/kg, po or ip measured after 16 hrs by LC-MS analysis	Mus musculus	1		organism-based format	Scientific Literature
15.	ALA4375447	F	Anti-absorptive activity in loperamide-induced CD-1 mouse model of constipation assessed as improvement in fecal pellet number at 5 mg/kg, po administered via gavage for 1 hr prior to loperamide challenge and measured after 3 hrs	Mus musculus	1		organism-based format	Scientific Literature
16.	ALA4375448	F	Anti-absorptive activity in loperamide-induced CD-1 mouse model of constipation assessed as improvement in stool water content at 5 mg/kg, po administered via gavage for 1 hr prior to loperamide challenge and measured after 3 hrs	Mus musculus	1		organism-based format	Scientific Literature
17.	ALA5053125	B	Inhibition of mouse Slc26a3 transfected in rat FRT cells preincubated with forskolin, 8-Br-cGMP and PMA and measured by fluorescence assay	Mus musculus	51		cell-based format	Patent Bioactivity Data
18.	ALA5053140	F	In vivo inhibition of slc26a3 in loperamide-induced constipation model of female CD-1 mouse at 5 mg/kg, po assessed as reduction in stool weight	Mus musculus	2		organism-based format	Patent Bioactivity Data
19.	ALA5053141	F	In vivo inhibition of slc26a3 in loperamide-induced constipation model of female CD-1 mouse at 5 mg/kg, po assessed as reduction in pellet number	Mus musculus	2		organism-based format	Patent Bioactivity Data
20.	ALA5053142	F	In vivo inhibition of slc26a3 in loperamide-induced constipation model of female CD-1 mouse at 5 mg/kg, po assessed as reduction in stool water content	Mus musculus	2		organism-based format	Patent Bioactivity Data